

EDURANT® (rilpivirine) tablets, for oral use
EDURANT® PED (rilpivirine) tablets, for oral suspension
Media Statement – March 2024 – U.S. FDA Approves EDURANT® PED
(rilpivirine) for Certain Pediatric Patients Living with HIV-1

SUMMARY

- On March 19, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved EDURANT® PED (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naïve children (with HIV-1 RNA <100,000 copies/mL) at least 2 years of age and weighing at least 14 kg and less than 25 kg.
- Please click here for the link to the [Media Statement](#).¹

REFERENCE

1. Johnson & Johnson. U.S. FDA approves EDURANT® PED (rilpivirine) for certain pediatric patients living with HIV-1. 19 March 2024. Available at: <https://www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1>.